Impact of Diabetes Mellitus on Outcomes in Patients with Left Ventricular Assist Devices

Heart failure (HF) represents a significant health burden in the United States, resulting in substantial mortality and healthcare costs. Through the array of treatment options available, including lifestyle modifications, medications, and implantable devices, HF management has evolved. Left ventricu...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2024-07, Vol.12 (7), p.1604
Main Authors: Crugnola, William, Cinquina, Andrew, Mattimore, Daniel, Bitzas, Savannah, Schwartz, Jonathon, Zaidi, Saleem, Bergese, Sergio D
Format: Article
Language:English
Subjects:
Cardiomyopathy
Cardiovascular disease
chronic kidney disease
Comorbidity
Congestive heart failure
Diabetes
Diabetes mellitus
Dyslipidemia
Ejection fraction
Glucose
Heart failure
Heart transplants
Hemodynamics
Hemoglobin
Hyperglycemia
Hypoglycemia
Insulin resistance
Kidney diseases
left ventricular assist device
Microvasculature
Mortality
Optimization
Patients
Renal function
Vascular diseases
Vein & artery diseases
Ventricle
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure (HF) represents a significant health burden in the United States, resulting in substantial mortality and healthcare costs. Through the array of treatment options available, including lifestyle modifications, medications, and implantable devices, HF management has evolved. Left ventricular assist devices (LVADs) have emerged as a crucial intervention, particularly in patients with advanced HF. However, the prevalence of comorbidities such as diabetes mellitus (DM) complicates treatment outcomes. By elucidating the impact of DM on LVAD outcomes, this review aims to inform clinical practice and enhance patient care strategies for individuals undergoing LVAD therapy. Patients with DM have higher rates of hypertension, dyslipidemia, peripheral vascular disease, and renal dysfunction, posing challenges to LVAD management. The macro/microvascular changes that occur in DM can lead to cardiomyopathy and HF. Glycemic control post LVAD implantation is a critical factor affecting patient outcomes. The recent literature has shown significant decreases in hemoglobin A1c following LVAD implantation, representing a possible bidirectional relationship between DM and LVADs; however, the clinical significance of this decrease is unclear. Furthermore, while some studies show increased short- and long-term mortality in patients with DM after LVAD implantation, there still is no literature consensus regarding either mortality or major adverse outcomes in DM patients.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12071604